132 related articles for article (PubMed ID: 34265779)
1. Transporters, TBC1D4, and ARID5B Variants to Explain Glycated Hemoglobin Variability in Patients with Type 2 Diabetes.
Gonzalez-Covarrubias V; Sánchez-Ibarra H; Lozano-Gonzalez K; Villicaña S; Texis T; Rodríguez-Dorantes M; Cortés-Ramírez S; Lavalle-Gonzalez F; Soberón X; Barrera-Saldaña H
Pharmacology; 2021; 106(11-12):588-596. PubMed ID: 34265779
[TBL] [Abstract][Full Text] [Related]
2. Lack of effect of the SLC47A1 and SLC47A2 gene polymorphisms on the glycemic response to metformin in type 2 diabetes mellitus patients.
Raj GM; Mathaiyan J; Wyawahare M; Priyadarshini R
Drug Metab Pers Ther; 2018 Dec; 33(4):175-185. PubMed ID: 30433870
[TBL] [Abstract][Full Text] [Related]
3. Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.
Pérez-Gómez N; Fernández-Ortega MD; Elizari-Roncal M; Santos-Mazo E; la Maza-Pereg L; Calvo S; Alcaraz R; Sanz-Solas A; Vinuesa R; Saiz-Rodríguez M
Pharmacogenomics; 2023 Aug; 24(12):651-663. PubMed ID: 37610884
[TBL] [Abstract][Full Text] [Related]
4. SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients.
He R; Zhang D; Lu W; Zheng T; Wan L; Liu F; Jia W
Diabetes Res Clin Pract; 2015 Jul; 109(1):57-63. PubMed ID: 26004431
[TBL] [Abstract][Full Text] [Related]
5. Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes.
Phani NM; Vohra M; Kakar A; Adhikari P; Nagri SK; D'Souza SC; Umakanth S; Satyamoorthy K; Rai PS
Pharmacogenomics; 2018 Jul; 19(11):905-911. PubMed ID: 29914345
[TBL] [Abstract][Full Text] [Related]
6. Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study.
Reséndiz-Abarca CA; Flores-Alfaro E; Suárez-Sánchez F; Cruz M; Valladares-Salgado A; Del Carmen Alarcón-Romero L; Vázquez-Moreno MA; Wacher-Rodarte NA; Gómez-Zamudio JH
J Clin Pharmacol; 2019 Oct; 59(10):1384-1390. PubMed ID: 31012983
[TBL] [Abstract][Full Text] [Related]
7. Genomic editing of metformin efficacy-associated genetic variants in SLC47A1 does not alter SLC47A1 expression.
Kalamajski S; Huang M; Dalla-Riva J; Keller M; Dawed AY; Hansson O; Pearson ER; ; Mulder H; Franks PW
Hum Mol Genet; 2022 Feb; 31(4):491-498. PubMed ID: 34505146
[TBL] [Abstract][Full Text] [Related]
8. Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis.
Dujic T; Zhou K; Yee SW; van Leeuwen N; de Keyser CE; Javorský M; Goswami S; Zaharenko L; Hougaard Christensen MM; Out M; Tavendale R; Kubo M; Hedderson MM; van der Heijden AA; Klimčáková L; Pirags V; Kooy A; Brøsen K; Klovins J; Semiz S; Tkáč I; Stricker BH; Palmer C; 't Hart LM; Giacomini KM; Pearson ER
Clin Pharmacol Ther; 2017 Jun; 101(6):763-772. PubMed ID: 27859023
[TBL] [Abstract][Full Text] [Related]
9. Differential increments of basal glucagon-like-1 peptide concentration among SLC47A1 rs2289669 genotypes were associated with inter-individual variability in glycaemic response to metformin in Chinese people with newly diagnosed Type 2 diabetes.
Liang H; Xu W; Zhou L; Yang W; Weng J
Diabet Med; 2017 Jul; 34(7):987-992. PubMed ID: 28321905
[TBL] [Abstract][Full Text] [Related]
10. Association of the SLC47A1 Gene Variant With Responses to Metformin Monotherapy in Drug-naive Patients With Type 2 Diabetes.
Kim H; Bae S; Yoon HY; Yee J; Gwak HS
J Clin Endocrinol Metab; 2022 Aug; 107(9):2684-2690. PubMed ID: 35639991
[TBL] [Abstract][Full Text] [Related]
11. Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients.
Hou W; Zhang D; Lu W; Zheng T; Wan L; Li Q; Bao Y; Liu F; Jia W
Mol Diagn Ther; 2015 Feb; 19(1):25-33. PubMed ID: 25573751
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients.
Xhakaza L; Abrahams-October Z; Pearce B; Masilela CM; Adeniyi OV; Johnson R; Ongole JJ; Benjeddou M
Drug Metab Pers Ther; 2020 Jun; 35(2):. PubMed ID: 32681778
[TBL] [Abstract][Full Text] [Related]
13. The influence of SLC22A3 rs543159 and rs1317652 genetic variants on metformin therapeutic efficacy in newly diagnosed patients with type 2 diabetes mellitus: 25 weeks follow-up study.
Taheri R; Kazerouni F; Mirfakhraei R; Kalbasi S; Shahrokhi SZ; Rahimipour A
Gene; 2022 May; 823():146382. PubMed ID: 35240257
[TBL] [Abstract][Full Text] [Related]
14. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
[TBL] [Abstract][Full Text] [Related]
15. The Usefulness of Diagnostic Panels Based on Circulating Adipocytokines/Regulatory Peptides, Renal Function Tests, Insulin Resistance Indicators and Lipid-Carbohydrate Metabolism Parameters in Diagnosis and Prognosis of Type 2 Diabetes Mellitus with Obesity.
Komosinska-Vassev K; Gala O; Olczyk K; Jura-Półtorak A; Olczyk P
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32917052
[TBL] [Abstract][Full Text] [Related]
16. A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin.
Goswami S; Yee SW; Xu F; Sridhar SB; Mosley JD; Takahashi A; Kubo M; Maeda S; Davis RL; Roden DM; Hedderson MM; Giacomini KM; Savic RM
Clin Pharmacol Ther; 2016 Nov; 100(5):537-547. PubMed ID: 27415606
[TBL] [Abstract][Full Text] [Related]
17. The influence of metformin transporter gene SLC22A1 and SLC47A1 variants on steady-state pharmacokinetics and glycemic response.
Ningrum VDA; Sadewa AH; Ikawati Z; Yuliwulandari R; Ikhsan MR; Fajriyah R
PLoS One; 2022; 17(7):e0271410. PubMed ID: 35905099
[TBL] [Abstract][Full Text] [Related]
18. Association between organic cation transporter genetic polymorphisms and metformin response and intolerance in T2DM individuals: a systematic review and meta-analysis.
Peng A; Gong C; Xu Y; Liang X; Chen X; Hong W; Yan J
Front Public Health; 2023; 11():1183879. PubMed ID: 37546319
[TBL] [Abstract][Full Text] [Related]
19. Metformin decreases glycated albumin to glycated haemoglobin ratio in patients with newly diagnosed type 2 diabetes.
Sumitani S; Morita S; Deguchi R; Hirai K; Mukai K; Utsu Y; Miki S; Sato B; Nakamura H; Kasayama S; Koga M
Ann Clin Biochem; 2015 Jan; 52(Pt 1):76-81. PubMed ID: 24604630
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes.
Tkáč I; Klimčáková L; Javorský M; Fabianová M; Schroner Z; Hermanová H; Babjaková E; Tkáčová R
Diabetes Obes Metab; 2013 Feb; 15(2):189-91. PubMed ID: 22882994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
